SLRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Salarius Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for Salarius Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Salarius Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Salarius Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Salarius Pharmaceuticals is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Salarius Pharmaceuticals (NAS:SLRX) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Salarius Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Tess Burleson | director | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Jonathan I Lieber | director | C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451 |
William K. Mcvicar | director | C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421 |
Arnold C Hanish | director | 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119 |
Mark J Rosenblum | officer: Exec VP Finance, Interim CFO | 3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244 |
David J. Arthur | director, officer: Chief Executive Officer | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Scott Jordan | officer: Chief Financial Officer | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Mccreedy Bruce J Jr. | director | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Jonathan P Northrup | director | 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021 |
Pao-yu Chuang | officer: Controller | 2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021 |
Paul Lammers | director | 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380 |
Boston Foundation, Inc. | 10 percent owner | 75 ARLINGTON STREET, BOSTON MA 02116 |
Christoph H Westphal | 10 percent owner | C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142 |
Longwood Fund Ii, L.p. | 10 percent owner | 800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199 |
Roger D Tung | director | 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By Marketwired • 07-11-2023
By GuruFocus Research • 02-09-2024
By Marketwired • 02-03-2025
By GuruFocus Research • 02-09-2024
By Marketwired • 01-14-2025
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 01-13-2025
By sperokesalga sperokesalga • 05-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.